H. Mucke

H. Mucke, Cristian Nogales, Alexandra Petraina, 2022, Repurposing soluble guanylate cyclase stimulators from one to another isoform within the ROCG signalling module.

Drug Repurposing Patent Applications April-June 2019.

H. Mucke, 2020, Assay and drug development technologies.

Patent highlights December 2021-January 2022.

H. Mucke, 2022, Pharmaceutical patent analyst.

Relating patenting and peer-review publications: an extended perspective on the vascular health and risk management literature

H. Mucke, 2011, Vascular health and risk management.

Drug Repurposing Patent Applications April-June 2018.

H. Mucke, 2018, Assay and drug development technologies.

Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory

H. Mucke, 2017, Front. Pharmacol..

Alcohol-induced organic cerebral psychosyndromes: partial reversal of cognitive impairments assisted by dihydroergocristine

L. Havelec, H. Mucke, M. Rainer, 2008, Psychopharmacology.

Pulmonary arterial hypertension: on the way to a manageable disease.

H. Mucke, 2008, Current opinion in investigational drugs.

Drug Repurposing Patent Applications July-September 2019.

H. Mucke, 2020, Assay and drug development technologies.

Drug Repurposing Patent Applications October-December 2015.

H. Mucke, 2016, Assay and drug development technologies.

Patent highlights April-May 2015.

H. Mucke, 2015, Pharmaceutical patent analyst.

Patent highlights August-September 2017.

H. Mucke, 2018, Pharmaceutical patent analyst.

Patent highlights, August-September 2019.

H. Mucke, 2020, Pharmaceutical patent analyst.

Patent highlights April-May 2020.

H. Mucke, 2020, Pharmaceutical patent analyst.

Drug Repurposing Patent Applications April to June 2020.

H. Mucke, 2020, Assay and drug development technologies.

Recent trends in ADHD pharmacotherapy: do we need more divided attention?

H. Mucke, 2000, IDrugs : the investigational drugs journal.

Twenty years of cholinergic intervention in Alzheimer's disease: A tale of disappointment and ultimate confidence.

H. Mucke, M. Rainer, 1998, International journal of psychiatry in clinical practice.

Drug Repurposing Patent Applications January-March 2021.

H. Mucke, 2021, Assay and drug development technologies.

No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia

K. Jellinger, H. Mucke, M. Haushofer, 2000, Journal of Neural Transmission.

Patent highlights: February-March 2016.

H. Mucke, 2016, Pharmaceutical patent analyst.

Zotepine for Behavioural and Psychological Symptoms in Dementia

H. Mucke, M. Haushofer, S. Kasper, 2004, CNS Drugs.

Patent highlights October-November 2019.

H. Mucke, 2020, Pharmaceutical patent analyst.

Patent highlights October-November 2021.

H. Mucke, 2022, Pharmaceutical patent analyst.

Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.

H. Mucke, 2009, IDrugs : the investigational drugs journal.

Patent Highlights April-May 2016.

H. Mucke, 2016, Pharmaceutical patent analyst.

Therapies in development for the treatment of migraine

H. Mucke, 2002, Expert opinion on investigational drugs.

Aldose Reductase Inhibitors for Diabetic Cataract: A Study of Disclosure Patterns in Patents and Peer Review Papers

H. Mucke, E. Mucke, 2014 .

Drug Repurposing Patent Applications October: December 2021.

H. Mucke, 2022, Assay and drug development technologies.

Drug Repurposing Patent Applications July-September 2017.

H. Mucke, 2017, Assay and drug development technologies.

Preclinical studies with galanthamine

H. Mucke, Hermann Am Mucke, 1997 .

Patent Highlights April - May 2022.

H. Mucke, 2022, Pharmaceutical patent analyst.

Pharmacological therapies for cataract and refractive errors: landscaping niches of ocular drug patenting.

H. Mucke, P. Mucke, E. Mucke, 2012, Pharmaceutical patent analyst.

Zotepine for Behavioural and Psychological Symptoms in Dementia: An Open-Label Study

H. Mucke, M. Haushofer, M. Rainer, 2004, CNS drugs.

Drug Repurposing Patent Applications October-December 2018.

H. Mucke, 2019, Assay and drug development technologies.

Patent highlights October-November 2015.

H. Mucke, 2016, Pharmaceutical patent analyst.

Patent highlights December 2020-January 2021.

H. Mucke, 2021, Pharmaceutical patent analyst.

Patent highlights February-March 2020.

H. Mucke, 2020, Pharmaceutical patent analyst.

Indications for the presence of antibodies cross-reactive with HTLV-I/II, but not HIV, in patients with myelodysplastic syndrome.

H. Mucke, O. Krieger, D. Lutz, 1992, Clinical immunology and immunopathology.

Drug Repurposing Patent Applications October-December 2022.

H. Mucke, 2023, Assay and drug development technologies.

Patent highlights February-March 2019.

H. Mucke, 2019, Pharmaceutical patent analyst.

Association of human T-cell leukemia virus and myelodysplastic syndrome in a central European population.

M. Pfeilstöcker, H. Karlic, H. Mucke, 1997, Cancer research.

Drug Repurposing Patent Applications April-June 2021.

H. Mucke, 2021, Assay and drug development technologies.

Evaluation of an indirect immunofluorescence assay for confirmation of human immunodeficiency virus type 1 antibody in U.S. blood donor sera

H. Mucke, C. Fang, A. Williams, 1992, Journal of clinical microbiology.

Drug Repurposing Patent Applications October-December 2019.

H. Mucke, 2020, Assay and drug development technologies.

Patent highlights August-September 2016.

H. Mucke, 2017, Pharmaceutical patent analyst.

Patent highlights June-July 2019.

H. Mucke, 2019, Pharmaceutical patent analyst.

CEP-1347 (Cephalon).

H. Mucke, 2003, IDrugs : the investigational drugs journal.

Drug Repurposing Patent Applications July-September 2022.

H. Mucke, 2022, Assay and drug development technologies.

Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity?

H. Mucke, 2009 .

Patent highlights February-March 2017.

H. Mucke, 2017, Pharmaceutical patent analyst.

Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study

H. Mucke, C. Jagsch, M. Rainer, 2011, Journal of Neural Transmission.

NOX Inhibitors: From Bench to Naxibs to Bedside.

H. Schmidt, H. Mucke, Mahmoud H Elbatreek, 2020, Handbook of experimental pharmacology.

Drug Repurposing Patent Applications October-December 2016.

H. Mucke, 2017, Assay and drug development technologies.

Alcohol-induced organic cerebral psychosyndromes: partial reversal of cognitive impairments assisted by dihydroergocristine

L. Havelec, H. Mucke, M. Rainer, 1996, Psychopharmacology.

The case of galantamine: repurposing and late blooming of a cholinergic drug

H. Mucke, 2015, Future science OA.

Patent highlights February-March 2021.

H. Mucke, 2021, Pharmaceutical patent analyst.

Patent highlights June-July 2020.

H. Mucke, 2020, Pharmaceutical patent analyst.

Patent highlights December 2016-January 2017.

H. Mucke, 2017, Pharmaceutical patent analyst.

Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics

K. Jellinger, H. Mucke, M. Haushofer, 2001, Journal of Neural Transmission.

Ginkgo biloba extract EGb 761® in the treatment of dementia: a pharmacoeconomic analysis of the Austrian setting

S. Schlaefke, H. Mucke, M. Rainer, 2013, Wiener klinische Wochenschrift.

Drug Repurposing Patent Applications January-March 2023.

H. Mucke, 2023, Assay and drug development technologies.

From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide.

H. Mucke, 2016, Assay and drug development technologies.

Clomethiazole (Astra Arcus AB).

H. Mucke, 1999, IDrugs : the investigational drugs journal.

Localization and function of 5-HT2 receptors.

H. Mucke, 2002, IDrugs : the investigational drugs journal.

Genomics and dementia--new drug targets ahead?

H. Mucke, 2002, Journal of neural transmission. Supplementum.

Patent highlights August-September 2022.

H. Mucke, 2023, Pharmaceutical patent analyst.

Drug Repurposing Patent Applications July-September 2015.

H. Mucke, 2015, Assay and drug development technologies.

Patent highlights April-May 2018.

H. Mucke, 2018, Pharmaceutical patent analyst.

Drug Repurposing Patent Applications April-June 2023.

H. Mucke, 2023, Assay and drug development technologies.

Patent Highlights February-March 2022.

H. Mucke, 2022, Pharmaceutical patent analyst.

Patent highlights December 2022-January 2023.

H. Mucke, 2023, Pharmaceutical patent analyst.

Repurposing for Alzheimer’s and Parkinson’s Diseases

H. Mucke, 2017 .

Drug Repurposing Patent Applications January-March 2017.

H. Mucke, 2017, Assay and drug development technologies.

Patent Highlights June-July 2023.

H. Mucke, 2024, Pharmaceutical patent analyst.

Drug Repurposing Patent Applications July-September 2016.

H. Mucke, 2016, Assay and drug development technologies.

Patent Highlights June-July 2022.

H. Mucke, 2022, Pharmaceutical patent analyst.

Patent Highlights April-May 2023.

H. Mucke, 2024, Pharmaceutical patent analyst.

Drug Repurposing Patent Applications January-March 2016.

H. Mucke, 2016, Assay and drug development technologies.

Iguratimod: a new disease-modifying antirheumatic drug.

H. Mucke, 2012, Drugs of today.

Drug Repurposing Patent Applications January-March 2024.

H. Mucke, 2024, Assay and drug development technologies.